Trip to the Doctor with Short Graying Hair and an Impish Smile, Received Her Diagnosis: Ovarian Cancer, Stage 1C

Total Page:16

File Type:pdf, Size:1020Kb

Trip to the Doctor with Short Graying Hair and an Impish Smile, Received Her Diagnosis: Ovarian Cancer, Stage 1C a spring day in 2010, “Sandra,” then a 63-year- On old ice-skating instructor Trip to the Doctor with short graying hair and an impish smile, received her diagnosis: ovarian cancer, stage 1C. The rock-hard tumor Once taboo, psychedelics are making growing inside her abdomen was surgically removed almost immediately. She spent an enlightening medical comeback the next several months soldiering through by Jennifer Bleyer exhausting rounds of chemotherapy. Oddly, it was only once she was in remission that Photographs by Matthew Septimus the worst began. Sandra found herself crippled with anxiety. An online support group for ovarian cancer patients exacerbated her worry as other women warned that it was not a question of if but when her cancer would return. She ate compulsively, which compounded her fear—the stomach pains she got once from scarfing down an entire bag of Halloween candy felt like a sure sign that the cancer was back. In the days leading up to her regular oncology appointments, she nearly hyperventilated with terror. On one such visit to the NYU Cancer Institute last spring, Sandra mentioned her anxiety to a nurse practitioner who told her about an unusual research project happening at the university. It was a study to assess the potential of psilocybin—a psychoactive compound found naturally in a wide variety of mushrooms—to alleviate psychological distress in cancer patients. Once in her college days, Sandra had tried mescaline, a psychedelic found in peyote and other cacti, and experienced a bad trip. She had felt trapped in a waking nightmare that didn’t end for nearly 24 hours, until someone gave her some Thorazine to force her to sleep. The idea of taking a similar drug made her nervous, but her anxiety was so crushing she had little to lose. That was how she came to be lying on a couch a few months later in a warm, silent room at the Bluestone Center for Clinical Research, a drug trial facility within NYU’s College of Dentistry. Wearing eyeshades and headphones, Sandra sensed herself being launched into a dark, infinite void. It was terrifying. She felt as if she was trapped in the hold of a ship, tossing Patients in the NYU violently in a storm. A panicked thought Psilocybin Cancer crossed her mind: Am I breathing? She Anxiety Study begin their forced herself to moan as she exhaled just hallucinatory experience to make sure that she wasn’t suffocating. wearing eyeshades and headphones as Soon, Sandra saw her own body. There doctors encourage was a black mass beneath her rib cage. She them to bear witness steeled herself and confronted the mass, to an inner world. 30 / SPRING 2013 / NYU NYU / SPRING 2013 / 31 recognizing it immediately as a vivid medicine at NYU, and the director of the accounts, however, their entry into modern became synonymous with everything that In an act nodding to manifestation of her own fear. Her fury Division of Alcoholism and Drug Abuse psychiatry didn’t begin until April 19, culturally earth-shattering era came to indigenous cultures that use psychedelics, boiled over. She yelled, “Get out! I won’t be at Bellevue Hospital, found it curious that 1943, when a Swiss biochemist named represent. patients in the NYU eaten alive!” In an instant, the black mass in his many years of treating addicts, he Albert Hofmann at Sandoz Laboratories Yet alongside promises of awakening study are presented was gone. had never seen one who was addicted to ingested a tiny amount of a chemical he came apocryphal stories of young people their psilocybin pill in “Then I started thinking about my psychedelics. had synthesized called d-lysergic acid jumping off buildings and burning their a ceramic chalice. family,” she remembers. “I was just In 2006, Ross was working under diethylamide, or LSD, which the company retinas by staring at the sun. In 1969, the overwhelmed with love. Totally bathed in the supervision of Jeffrey Guss, a clinical was developing as a potential circulatory Manson family’s grisly murders and the love. It wasn’t just my love for my children assistant professor of psychiatry who had and respiratory stimulant. Hofmann’s stabbing death of a fan at a Rolling Stones and my husband and my dearest friends— a long-standing interest in spirituality and experience was indescribably powerful concert were both linked to LSD. Whatever it was their love for me. It was all part of consciousness. One day, Guss (GSAS ’05) and surreal—he was certain he had therapeutic potential psychedelics held the same thing. I felt timelessness, that mentioned something called ayahuasca, become psychotic. He went on to report faded beside their perceived danger. I was part of an eternal existence. It was a psychoactive brew derived from an it to the scientific community, which Drug panic culminated in the passage the most magical, wonderful experience Amazonian plant that was rumored to developed a keen interest. of the Controlled Substances Act of I’ve ever had in my life.” cure addiction. Ross had never heard of it, By the 1950s, Sandoz was 1970, which established the federal five- manufacturing LSD for use in experiments tiered schedule of drug classifications; across Europe and North America. psychedelics, including LSD and “I felt timelessness, that I was More than a thousand clinical reports psilocybin, were categorized as Schedule part of an eternal existence,” about psychedelic research appeared I, meaning that they had a high potential in scholarly journals from the 1950s for abuse and no accepted medical says former patient Sandra. through the early ’70s, and as Ross use. The door on psychedelic research discovered, tens of thousands of subjects effectively slammed shut. realm of research as a serious scientist with ethnic-printed pillows, shelves Even months after the psilocybin’s but their conversation piqued his interest ingested LSD and other hallucinogens and not be tarred as a freak. He sought stocked with oversize books of Tibetan immediate afterglow had worn off, Sandra and he started researching beliefs about to examine its effects on alcoholism, surprised as Ross was to out Charles Grob, the head of child art, framed landscape photographs, warm felt more patient, calm, and centered the healing power of hallucinogens. He depression, schizophrenia, autism, and unearth this chapter in and adolescent psychiatry at Harbor- pools of lamplight, Buddha figurines, and, than ever before. And somehow, her fear was shocked by what he discovered. death anxiety. In 1958, the American American psychiatry, he UCLA Medical Center, who had started on dosing days, fresh fruit and flowers. of a cancer recurrence had disappeared “I felt like an archaeologist,” Ross Psychiatric Association held a conference Aswas intrigued to learn that research had conducting psychedelic research in the Notwithstanding the lovely room, completely. says. “American psychiatry looked very highlighting LSD psychotherapy, which quietly begun again. It started as a trickle mid ’90s. “He seemed like such a nice, psilocybin does present risks. Although seriously into the therapeutic applicability was thought to offer unprecedented in the early 1990s, when a psychiatrist normal guy who lived in the suburbs,” it is not known to induce addiction, only thing that Stephen of hallucinogen treatment models for access to the unconscious. Time and Life at the University of New Mexico got Ross says. “Not some fringe character.” overdose, or withdrawal symptoms, some Ross learned about a quarter century. There were tens of magazines covered the drug regularly and federal approval to examine the effects of With Grob’s encouragement, Ross, research has suggested it can bring about The psychedelic drugs thousands of research participants in the enthusiastically. Even the CIA developed dimethyltryptamine, or DMT, a powerful Guss, and another colleague, Anthony prolonged psychosis in people with a during his training as a psychiatrist United States, and my field of addiction an interest in the drug, testing its psychedelic that occurs throughout Bossis (GSAS ’91), a clinical assistant personal or family history of major mental was that they were highly dangerous. and alcohol was the most studied capabilities for mind control on unwitting the botanical world, on hundreds of professor of psychiatry and a palliative illness, so such patients are carefully A particularly bad taboo enveloped indication. And here it was, completely subjects as part of a covert operation volunteers. Soon, other scientists were care expert, joined together to propose screened out of the study. In the session LSD because it was known to trigger buried and suppressed.” called Project MKUltra. granted licenses for human subject a double-blind, placebo-controlled study itself, there may be some physical side psychosis. Yet Ross, a trim 42-year-old Indigenous cultures had used As psychedelic research proliferated, studies of Schedule I drugs, including Captionof psilocybin here n this treatment size and style.for anxiety Caption in here n effects, such as nausea, dizziness, and associate professor of psychiatry, child psychedelics for millennia as sources another avenue developed that would psilocybin and MDMA, the club drug thislate-stage size and style.cancer patients. In early tremors, but the more pronounced and adolescent psychiatry, and oral of divination and ritual healing. By all change the course of history. In 1960, two better known as Ecstasy. 2007, they received an investigational hazards are psychological. Periods of psychologists based at Harvard, Timothy Interesting results began to emerge. drug license from the Food and Drug transient anxiety can occur as patients PHOTO © MARTIN BOND/ALAMY © MARTIN PHOTO Leary and Richard Alpert (now known At the Johns Hopkins University School of Administration and the Drug Enforcement navigate the challenging psychological as Ram Dass), initiated the Harvard Medicine, for instance, a controlled study Administration, as well as approvals from material related to cancer.
Recommended publications
  • Around the Corner Canadian Equity Research Emerging Companies and Industries to Watch 3 March 2020
    Around the Corner Canadian Equity Research Emerging companies and industries to watch 3 March 2020 Tania Gonsalves, CFA | Analyst | Canaccord Genuity Corp. (Canada) | [email protected] | 1.416.996.8346 Scott McFarland | Associate | Canaccord Genuity Corp. (Canada) | [email protected] | 1.416.998.7202 Around the Corner highlights what we believe are some of the most exciting Psychedelic-derived medicines and therapies emergent private companies in Canada, and/or industry themes and trends which are yet to be fully represented in the Mental health miracle or another bad trip? public markets. When most of us think of psychedelic drugs, we think of the 1960s counterculture. We We aim to offer insight into early industry think of anti-establishment, anti-war, anti-capitalist hippies, Woodstock, tie-dye, Lucy in trends, educate investors about private the Sky, peace, love and bell bottom jeans. But before psychedelics became ingrained in companies that are making a mark, and the counterculture, they were found in a lab. The first wave of scientific research on identify companies that may enter the psychedelics took place between 1950-65. Sandoz Pharmaceutics, what is now Novartis public markets in the future. AG (NVS-NYSE), the third largest pharmaceutical company in the world, used to market We do not provide any ratings or price LSD and psilocybin for psychotherapeutic purposes. Psychedelics weren’t born of the targets, nor should any be inferred, for counterculture. They were killed by it. The proliferation of recreational use spurred any uncovered company featured in government intervention and by 1971, psilocybin, LSD, ibogaine, mescaline, peyote, Around the Corner.
    [Show full text]
  • Responding to an Urgent Mental Health Crisis Challenges and Solutions for People Suffering with Treatment-Resistant Depression
    Responding to an urgent mental health crisis Challenges and solutions for people suffering with treatment-resistant depression A White Paper from COMPASS Pathways August 2021 Contents Foreword from George Goldsmith ..............................................................................................................03 Introduction ........................................................................................................................................................05 Executive summary . .........................................................................................................................................06 Part I: Treatment-resistant depression - background and challenges .................................................08 o Mental health disorders o Depression: an overview o Major depressive disorder and treatment-resistant depression o Suicide and treatment-resistant depression o Mental health care spending and use of services Part II: Current approaches and limitations for treatment of depression ...........................................15 o A fragmented and inaccessible mental health care system o Treatment approaches for depression o Psychotherapy o Drug therapy o Physical (somatic) therapies o Lack of research and development for new drug treatments Part III: Emerging solutions in treatments for depression ......................................................................24 o Emerging treatment options and the challenges of getting these to patients o Psychedelic therapies: a new frontier
    [Show full text]
  • Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms
    Dominican Scholar Physician Assistant Studies | Student Department of Physician Assistant Articles Studies 2020 Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms Sofia Beck Dominican University of California https://doi.org/10.33015/dominican.edu/2020.PAS.10 Survey: Let us know how this paper benefits you. Recommended Citation Beck, Sofia, "Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms" (2020). Physician Assistant Studies | Student Articles. 7. https://doi.org/10.33015/dominican.edu/2020.PAS.10 This Article is brought to you for free and open access by the Department of Physician Assistant Studies at Dominican Scholar. It has been accepted for inclusion in Physician Assistant Studies | Student Articles by an authorized administrator of Dominican Scholar. For more information, please contact [email protected]. ABSTRACT Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders. Studies involving the psychedelic serotonin agonist, psilocybin, are currently experiencing a resurgence as an alternative for patients who are unresponsive to traditional treatments. Clinical trials using psilocybin in combination with psychotherapy have demonstrated sustained reductions in depression and/or anxiety symptoms. When used in medical settings, it has shown to be safe, with few side effects and no risk of dependence. However, this psychedelic compound faces many stigmas and these results have yet to be compared to current treatments or in larger populations.
    [Show full text]
  • Can Magic Mushrooms Heal Us? - the New York Times
    3/22/2021 Opinion | Can Magic Mushrooms Heal Us? - The New York Times Can Magic Mushrooms Heal Us? A very promising mental health experiment is taking shape in Oregon. By Ezra Klein Opinion Columnist March 18, 2021 Gov. Kate Brown of Oregon announced the members of the state’s newly formed Psilocybin Advisory Board this week. Why does Oregon need an official board to offer advice about the active ingredient in magic mushrooms, you ask? Because Oregon is about to become the first state in the country to try to build a support infrastructure through which psychedelic mushrooms can be woven into everyday life. This framework is different from what we’ve seen before: not legalization, not medicalization, but therapeutic use, in licensed facilities, under the guidance of professionals trained to guide psychedelic experiences. Whoa. “Like many, I was initially skeptical when I first heard of Measure 109,” Brown said in a statement. “But if we can help people suffering from PTSD, depression, trauma and addiction — including veterans, cancer patients, and others — supervised psilocybin therapy is a treatment worthy of further consideration.” [Listen to “The Ezra Klein Show,” a podcast about ideas that matter.] Measure 109, the Oregon Psilocybin Services Act, approved as a ballot measure in November, is the brainchild of Tom and Sheri Eckert, who shared a therapy practice in Portland. In 2015, the Eckerts read an article by Michael Pollan in The New Yorker titled “The Trip Treatment.” The article described the emerging research around using psychedelics as a therapeutic tool and unearthed the largely forgotten pre-Timothy Leary period in which psychedelics were widely used by psychiatrists.
    [Show full text]
  • Experience of Music Used with Psychedelic Therapy: a Rapid Review and Implications
    Downloaded from https://academic.oup.com/jmt/advance-article-abstract/doi/10.1093/jmt/thaa006/5813582 by University of Birmingham user on 10 April 2020 Journal of Music Therapy, XX(XX), 2020, 1–33 doi:10.1093/jmt/thaa006 © The Author(s) 2020. Published by Oxford University Press on behalf of American Music Therapy Association. All rights reserved. For permissions, please e-mail: [email protected] Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications Clare O’Callaghan, AM, PhD, MMus, BMus, BSW, RMT Caritas Christi Hospice & Department of Psychosocial Cancer Care Research, St Vincent’s Hospital, Melbourne, Australia Department of Medicine, St Vincent’s Hospital, and Melbourne Conservatorium of Music, The University of Melbourne, Melbourne, Australia Daniel J. Hubik, MBBS, M. Psychiatry, FRANZCP Department of Psychosocial Cancer Care Research, St Vincent’s Hospital, Melbourne, Australia Justin Dwyer, MBBS Psychiatry, FRANZCP Department of Psychosocial Cancer Care Research, St Vincent’s Hospital, Melbourne, Australia Martin Williams, PhD Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia PRISM Inc., Melbourne, Australia Margaret Ross, PsyD, BSocSci, MAPS, FCCLP Caritas Christi Hospice & Department of Psychosocial Cancer Care Research, St Vincent’s Hospital, Melbourne, Australia Bonny Method of Guided Imagery and Music emerged following dis- continuation of psychedelic therapy research in the early 1970s, but psychedelic therapy research has since revived. Music remains a vital component. This study examined participants’ experiences of music in psychedelic therapy research. A rapid review of qualitative and This study was conducted while the authors were clinically working at St Vincent’s Hospital Melbourne. Address correspondence concerning this article to Clare O’Callaghan, PhD, RMT, Caritas Christi Hospice, St Vincent’s Hospital, 41 Victoria Parade, Fitzroy, Australia, 3065.
    [Show full text]
  • Legalising Access to Psilocybin to End the Agony of Cluster Headaches*
    ORGANISATION FOR THE PREVENTION OF INTENSE SUFFERING WWW.PREVENTSUFFERING.ORG POLICY PAPER LEGALISING ACCESS TO PSILOCYBIN TO END THE AGONY OF CLUSTER HEADACHES* *SUICIDE HEADACHES/HORTON’S NEURALGIA An ethical and evidence-based approach to treating one of the most excruciating conditions known to medicine. OPISNOVEMBER 2020 Legalising Access to Psilocybin to End the Agony of Cluster Headaches An ethical and evidence-based approach to treating one of the most excruciating conditions known to medicine CONTENTS Executive summary 2 Cluster headaches: a public health emergency 3 Patients’ descriptions of their pain 5 Standard treatments: benefits and shortcomings 6 Efectiveness of psilocybin and related chemicals 7 Patient testimonials of efcacy 10 Patients’ experiences represent powerful, essential evidence 14 Safety of psilocybin and other indoleamines 15 Cost 16 Legal status 16 Consequences of current drug policies for cluster headache patients 17 Ethical considerations 18 Human rights perspective 19 Policy options and recommendations 20 Possible concerns and responses 22 Co-signatories 23 EXECUTIVE SUMMARY Approximately 8 million people worldwide are aficted with possibly the most excruciating condition known to medicine: cluster headaches. Patients endure immense sufering, and many commit suicide to escape the pain. Current medical options are inadequate. Fortunately there is now clear evidence that psilocybin and chemically related substances are efective for many patients in preventing and aborting attacks. However, their legal status in most countries makes it difcult for patients to access them. Governments can dramatically improve the quality of life for many of their citizens, with little or no additional cost or risk, by removing the legal barriers to cluster headache patients accessing psilocybin and related compounds for therapeutic purposes.
    [Show full text]
  • Psychedelics and Mania Review Paper
    medRxiv preprint doi: https://doi.org/10.1101/2021.04.02.21254838; this version posted April 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies David E. Garda, Mollie M. Pleetb, c, Ellen R. Bradleyb, c, Andrew Pennb, Matthew L. Gallensteina, Lauren S. Rileya, Meghan DellaCrossed, Emily Garfinklee, Erin E. Michalakf, Joshua D. Woolleyb, c aSan Francisco State University, San Francisco, CA USA bUniversity of California San Francisco, San Francisco, CA USA cSan Francisco Veteran's Affairs Medical Center, San Francisco, CA USA dThe Wright Institute, Berkeley, CA USA ePalo Alto University-Pacific Graduate School of Psychology, Palo Alto, CA USA fUniversity of British Columbia, Vancouver, BC Canada Corresponding author: David E. Gard, Ph.D. Department of Psychology, San Francisco State University 1600 Holloway Ave San Francisco, California 94132 USA [email protected] Sources of direct funding, support, or sponsorship ● Dr. Woolley is funded in part via VA CSR&D 1IK4CX002090-01. Grant title: Quantifying and Treating Social Deficits in Veterans with Mental Illness: a Five Year Plan. Role of the sponsor ● Not applicable Potential conflicts of interest ● Dr. Woolley is a paid consultant for Psilo Scientific Ltd. and Silo Pharma. Abstract: 250 words Text: 4998 words Number of Figures: 1 Number of Tables: 2 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • STATE of HAWAII Testimony COMMENTING on HB2567
    DAVID Y. IGE BRUCE S. ANDERSON, PHD GOVERNOR OF HAWAII DIRECTOR OF HEALTH STATE OF HAWAII DEPARTMENT OF HEALTH P. O. Box 3378 Honolulu, HI 96801-3378 [email protected] Testimony COMMENTING on HB2567 RELATING TO PSILOCYBIN. REP. JOHN M. MIZUNO, CHAIR HOUSE COMMITTEE ON HEALTH Hearing Date: January 30, 2020 Room Number: 329 1 Fiscal Implications: $50,000 appropriation is recommended for meeting facilitation and 2 research services. 3 Department Testimony: The Department of Health (DOH) takes no position on the merits of 4 medicinal psilocybin. 5 However, establishing the Working Group pursuant to Session Law subjects it to chapter 92 6 “sunshine” or “open meetings” requirements that increase administrative burden but which to not 7 add commensurate value to the public – no public assets are at stake and there is no binding 8 public policy impacts. 9 The department respectfully recommends exempting the Working Group from chapter 92, or 10 preferably establishing it through Concurrent Resolution. 11 If Session Law is the preferred method, DOH recommends a modest appropriation for meeting 12 facilitation and basic research services. Since there is no existing academic or professional 13 foundation for medicinal psilocybin the Working Group will need research support to synthesize 14 the multidisciplinary elements for this novel public policy topic. 15 Thank you for the opportunity to testify. 16 House Committee on Health Clarity Project ​Strongly Supports​: HB2567 Dear Chair Mizuno, Vice Chair Kobayashi, and Members of the Committee, My name is Helen Cho, and I am here today representing the Clarity Project, a citizen’s initiative that aims to expand patient access to include psilocybin-assisted therapy modalities in Hawaii.
    [Show full text]
  • The Therapeutic Potential of Psilocybin
    molecules Review The Therapeutic Potential of Psilocybin Henry Lowe 1,2,3,4, Ngeh Toyang 2,3 , Blair Steele 1,*, Henkel Valentine 1, Justin Grant 1,5, Amza Ali 1,5, Wilfred Ngwa 6 and Lorenzo Gordon 7 1 Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica; [email protected] (H.L.); [email protected] (H.V.); [email protected] (J.G.); [email protected] (A.A.) 2 Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA; ngeh.toyang@flavocure.com 3 Flavocure Biotech Inc., Baltimore, MD 21202, USA 4 Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA 5 The Psyence Group, Toronto, ON M5J 2J1, Canada 6 Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; [email protected] 7 Caribbean School of Medical Sciences, Kingston 99999, Jamaica; [email protected] * Correspondence: [email protected]; Tel.: +876-926-8502 Abstract: The psychedelic effects of some plants and fungi have been known and deliberately ex- ploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics.
    [Show full text]
  • Yale Manual for Psilocybin-Assisted Therapy of Depression
    Yale Manual for Psilocybin-Assisted Therapy of Depression Version 4.2 Revised August 2019 Manual Co-Authors Jeffrey Guss, MD RoBert Krause, DNP APRN-BC Jordan Sloshower, MD, MSc Ryan Wallace, MD, MPH 2 Acknowledgements We express deep gratitude to Both the early and contemporary pioneers of this work—the scientists, authors, practitioners, guides, research volunteers, and organizations whose work with entheogens kept their possibilities alive - and who campaigned to revive and extend the study of entheogens for the benefit of others. Without these pioneers, this study and the majority of research related to the transformative and therapeutic benefits of entheogens would not exist. Thanks to funders: Yale University Department of Psychiatry Carey and Claudia TurnBull Heffter Research Institute Usona Research Institute Additional thanks: Dr. Jeffrey Guss, MD of NYU for his role as mentor and guide Members and faculty of the Yale Psychedelic Science Group 3 TABLE OF CONTENTS 1.0 INTRODUCTION 1.1 Goals of this Manual 1.2 Essential Elements of the Therapeutic Method 1.2a General Elements of Psychedelic-Assisted Therapy 1.2b Theoretical Orientations of Psilocybin-Assisted Therapy for Depression 1.2c Why utilize Acceptance and Commitment Therapy in Psilocybin- assisted therapy for Major Depressive Disorder? 2.0 THERAPIST FOUNDATION 2.1 Essential Therapist Background 2.2 Specialized Therapist Skills 3.0 SET and SETTING: THERAPIST PREPARATION 3.1 Set: The participant’s inner world 3.2 Preparing the Physical Setting 3.3 Preparing Social Support
    [Show full text]
  • Clinical Trials of Psilocybin and Ecstasy As Treatments for Depression And
    Feature THE RISE OF PSYCHEDELIC PSYCHIATRY Clinical trials of psilocybin and ecstasy as treatments for depression and post-traumatic stress disorder are starting to give results, but approvals will be challenging. By Paul Tullis n a sunny day in London in 2015, Kirk lovely, and especially Robin,” Rutter recalls. bejewelled structures. Then his mind went to Rutter rode the Tube to Hammer- Carhart-Harris led him to a room with a mag- work on his grief. smith Hospital in hopes of finally netic resonance imaging (MRI) machine, so The Imperial study was one of a spate of putting an end to his depression. researchers could acquire a baseline of his clinical trials launched over the past few years Rutter had lived with the condi- brain activity. Then he showed Rutter where using illicit psychedelic drugs such as psilo- tion off and on for years, but the he would spend his time while on the drug. cybin, lysergic acid diethylamide (LSD) and burden had grown since the death Carhart-Harris asked him to lie down and played MDMA (3,4-methylenedioxymethampheta- of his mother in 2011, followed by a him some of the music that would accompany mine, also known as molly or ecstasy) to treat Orelationship break-up and a car accident the the session. He explained that he would have mental-health disorders, generally with the year after. It felt as if his brain was stuck on on hand a drug that could neutralize the hallu- close guidance of a psychiatrist or psycho- what he describes as “an automatic circuit”, cinogen, if necessary.
    [Show full text]
  • Psychedelics, Trauma & Addiction
    the psychedelic renaissance (a) brain on placebo rcpsych in scotland Dr James Hawkins (b) brain on psilocybin addictions faculty conference Psychedelic Health Petri G. et al. (2014) 5th march 2021 Professionals Network sequence of talks this morning jake hawthorn introduction to psychedelics mdma-assisted psychotherapy ben sessa for alcohol use disorder broader research evidence, james hawkins mechanisms and education for addiction treatments a quick ’aerial view’ ➢ broader overall context ➢ what evidence supports the use of psychedelics in addiction treatment? ➢ how do psychedelic treatments work? ➢ education, training & the psychedelic health professionals network broader overall context ❖ who? ❖ why? ❖ what? ❖ how? ❖ where? who takes psychedelics? extrapolating mdma psilocybin psychedelics from dutch & us figures 3% annual 9.7% lifetime 17.4% lifetime scotland 5.5 m 165,000 533,500 957,000 uk 6 6 6 53.9 m 1.6 x 10 5.2 x 10 9.4 x 10 Van Laar MW, Van Gestel B, Cruts AAN, et al. (2019) Nationale Drug Monitor. Jaarbericht 2018. Utrecht, The Netherlands: Trimbos Instituut. Yockey, A. & King, K. (2021). “Use of psilocybin (“mushrooms”) among US adults: 2015–2018” J Psychedelic Studies. Jan 21. SAMHSA. (2020). ”17.4% of US adults have used a psychedelic." why do people take psychedelics? what are psychedelics? ‘psychedelic’ means ’mind revealing’ … a term introduced by British psychiatrist, Humphrey Osmond, in the 1950’s ❖ classic psychedelics (5-HT2A receptor agonists) ▪ psilocybin, LSD, DMT/ayahuasca, mescaline ❖ entactogens/empathogens ▪ MDMA, MDA, MMDA, 2C-series, etc ❖ dissociatives ▪ ketamine, nitrous oxide, salvia divinorum, PCP ❖ unique substances ▪ ibogaine, mad honey, etc classification by Kim Kuypers, researcher at Maastricht University, Netherlands how are psychedelics taken? different methods of ❖ orally ingestion produce different outcomes: ❖ inhaled ❖ nasally bioavailability ❖ sublingually predictability ❖ intramuscularly speed of onset ❖ intravenously duration of action ❖ rectally, etc side effects risk profile where: set Kettner, H.
    [Show full text]